Linked Data API

Show Search Form

Search Results

179004
registered interest false remove filter
date less than 2015-02-10more like thismore than 2015-02-10
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Hereditary Diseases remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, with reference to Part 5 (a) (ii) of the Mitochndrial Donation Regulations 2015, how the Human Fertilisation and Embryology Authority plans to define a "significant risk" of having or developing serious mitochondrial disease. more like this
tabling member constituency Stoke-on-Trent South more like this
tabling member printed
Robert Flello more like this
uin 224080 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-02-23more like thismore than 2015-02-23
answer text <p>The Human Fertilisation and Embryology Authority has advised that if Parliament passes the Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it will need to design a regulatory process of which the consideration of “significant risk” is a part. In designing that process it will take into account, where relevant, the existing regulatory process for embryo testing (preimplantation genetic diagnosis).</p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
question first answered
less than 2015-02-23T16:05:17.44Zmore like thismore than 2015-02-23T16:05:17.44Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
1569
label Biography information for Robert Flello more like this
178544
registered interest false remove filter
date less than 2015-02-09more like thismore than 2015-02-09
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Hereditary Diseases remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what estimate he has made of the cost to the public purse of (a) treatments for mitochondrial disease involving mitochondrial donation and (b) treatments for mitochondrial disease that do not involve mitochondrial donation in each of the next five financial years. more like this
tabling member constituency North Tyneside more like this
tabling member printed
Mrs Mary Glindon more like this
uin 223866 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-02-12more like thismore than 2015-02-12
answer text <p>The Government’s analysis of estimated costs and benefits is contained in the Impact Assessment that was laid in Parliament, together with the Draft Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, on 17 December 2014.</p><p> </p><p> </p><p> </p><p>The cost over 10 years was estimated at £11.1 million with the monetised benefit estimated at £329.2 million.</p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
question first answered
less than 2015-02-12T17:20:11.13Zmore like thismore than 2015-02-12T17:20:11.13Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4126
label Biography information for Mary Glindon more like this
177189
registered interest false remove filter
date less than 2015-02-02more like thismore than 2015-02-02
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Hereditary Diseases remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps his Department has taken to help early diagnosis of very long-chain acyl-CoA dehydrogenase deficiency. more like this
tabling member constituency Harlow more like this
tabling member printed
Robert Halfon more like this
uin 222853 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-02-09more like thismore than 2015-02-09
answer text <p>The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation.</p><p> </p><p> </p><p> </p><p>The UK NSC is currently reviewing newborn screening for very long chain acyl CoA dehydrogenase deficiency (VLCADD) against its internationally recognised criteria. A public consultation on the screening review opened on 21 November 2014 and will close on 23 February 2015. A copy of the consultation is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.screening.nhs.uk/fattyacidoxidation" target="_blank">http://www.screening.nhs.uk/fattyacidoxidation</a></p><p> </p><p> </p><p> </p><p>Improving education and awareness of rare diseases across the healthcare professions, including VLCADD, is a commitment in the UK Strategy for Rare Diseases. The Department continues to work closely with its delivery partners to implement the Strategy.</p><p> </p> more like this
answering member constituency Central Suffolk and North Ipswich more like this
answering member printed Dr Daniel Poulter more like this
question first answered
less than 2015-02-09T15:58:41.897Zmore like thismore than 2015-02-09T15:58:41.897Z
answering member
3932
label Biography information for Dr Dan Poulter more like this
tabling member
3985
label Biography information for Robert Halfon more like this
171143
registered interest false remove filter
date less than 2014-12-17more like thismore than 2014-12-17
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Hereditary Diseases remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he is taking to raise awareness of very long chain acyl-CoA dehydrogenase deficiency among (a) practitioners and (b) the public. more like this
tabling member constituency Barnsley Central more like this
tabling member printed
Dan Jarvis more like this
uin 219149 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-01-05more like thismore than 2015-01-05
answer text <p>Raising awareness of all rare diseases amongst practitioners and the public, including very long chain acyl-CoA dehydrogenase deficiency, is a commitment in the UK Strategy for Rare Diseases. The Department continues to work closely with NHS England to implement this commitment.</p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
question first answered
less than 2015-01-05T16:21:42.08Zmore like thismore than 2015-01-05T16:21:42.08Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4243
label Biography information for Dan Jarvis more like this